New drug candidate BL-M05D1 enters early human trials for tough cancers

NCT ID NCT07021066

Ongoing Disease control Sponsor: SystImmune Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 4 times

Summary

This early-phase study tests a new drug called BL-M05D1 in people with advanced or metastatic solid tumors (like stomach, pancreatic, or bile duct cancer) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 160 adults will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus biliary tract cancer Biliary Tract Neoplasms esophageal adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma metastatic malignant neoplasm neoplasm pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA BILIARY TRACT CANCER ESOPHAGEAL ADENOCARCINOMA GASTRIC ADENOCARCINOMA OTHER SOLID TUMORS

Contacts and locations

Locations

Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
HonorHealth

Scottsdale, Arizona, 85266, United States
NEXT Oncology San Antonio

San Antonio, Texas, 78229, United States
NEXT Oncology- Austin

Austin, Texas, 78758, United States
NEXT Oncology- Dallas

Dallas, Texas, 75039, United States
Ochsner Medical Center

New Orleans, Louisiana, 70121, United States
Sarah Cannon Research Institute - Oncology Partners

Nashville, Tennessee, 37203, United States
University of Colorado Health

Aurora, Colorado, 80045, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
Valkyrie Clinical Trials

Los Angeles, California, 90067, United States
Yale Cancer Center

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.